Press releases

Stockholm – February 20, 2025 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, will publish the report for the fourth quarter and the 2024 year-end report, at 08:00 CET on February 27, 2025. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session on February 27 at 09:00 CET

Stockholm, February 5, 2025 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that Jarl Ulf Jungnelius has informed the Board of Directors of his decision to step down from the Bord of Directors of Oncopeptides in which he has served since 2011. This due to personal reasons related to a change of domicile from Sweden

Stockholm, January 27, 2025 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that the positive reimbursement decision for its drug Pepaxti (melflufen) has been published in the Italian Official Journal (“IOJ”, It.: Gazetta Ufficiale). This marks the final regulatory step for the drug’s upcoming commercialization in Italy, confirming Oncopeptides’ expectation of first sales during H1, 2025

Stockholm, November 27, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that it has come to an agreement with the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) on the pricing and reimbursement of melflufen, branded in Europe as Pepaxti. The decision paves the way for the drug to be commercialized in Italy during H1, 2025

Stockholm – November 22, 2024 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO). Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that the composition of the Nomination Committee has been established

Stockholm – November 20, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that an evaluation of the activity of two peptide drug conjugates (PDCs) developed by Oncopeptides in relapsed or refractory Acute Myeloid Leukemia has been accepted as a poster and will be presented at the 66th annual American Society of Hematology (ASH) Meeting and Exposition. The conference takes place in San Diego, California between December 7-10

Stockholm – November 7, 2024 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the third quarter 2024

Stockholm – October 31, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, will publish the report for the third quarter of 2024, at 08:00 CET on November 7, 2024

Stockholm, September 12, 2024 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces it has signed an exclusive license and supply agreement with SCBIO Inc., a Korean pharmaceutical company for the commercialization of Oncopeptides’ flagship drug Pepaxti in South Korea

Stockholm – August 14, 2024 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the second quarter 2024